An official website of the United States Government 
Here's how you know

Official websites use .gov

.gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( lock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

You have accessed part of a historical collection on Some of the information contained within may be outdated and links may not function. Please contact the DOD Webmaster with any questions.
Immediate Release

HHS Adds $628 Million to Contract With Emergent BioSolutions to Secure CDMO Manufacturing Capacity for Operation Warp Speed

As part of the Trump Administration’s Operation Warp Speed, on Monday, the U.S. Department of Health and Human Services announced a task order with Emergent BioSolutions to advance manufacturing capabilities and capacity for a potential COVID-19 vaccine as well as therapeutics. The task order is worth approximately $628 million and falls under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of HHS’s Office of the Assistant Secretary for Preparedness and Response.

Under the task order, Emergent will commit contract development and manufacturing organization (CDMO) drug substance and drug product manufacturing capacity valued at approximately $542.75 million for production of COVID-19 vaccine candidates through 2021, in addition to an investment of approximately $85.5 million for the rapid expansion of Emergent’s viral and non-viral CDMO fill / finish capacity for vaccine and therapeutic manufacturing.

Before this task order announcement, Emergent had begun collaborating on development and manufacturing with Johnson & Johnson, Novavax, and Vaxart on their COVID-19 vaccine candidates. Johnson & Johnson’s candidate has received BARDA support. BARDA has invested since 2012 to expand domestic manufacturing capabilities in the United States, including creating three Centers for Innovation in Advanced Development and Manufacturing; one of the centers is managed by Emergent and becomes the first to be deployed for the Operation Warp Speed effort.

HHS Secretary Alex Azar issued the following statement:

“Within weeks after announcing Operation Warp Speed, President Trump has now brought on another key manufacturing partner for an eventual COVID-19 vaccine. Before a vaccine is even approved, Emergent’s manufacturing capabilities will pave the way for drug companies with candidates approaching approval to begin turning out doses. Securing more manufacturing capacity here in America for candidates that make it to the final stages of Operation Warp Speed will help get a vaccine to American patients without a day wasted.”

For more background on Operation Warp Speed, visit this page.